๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Triple-Negative Breast Cancer (TNBC)
Clinical trial register · China

Triple-Negative Breast Cancer (TNBC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 8 Beijing 7 Guangzhou 5 Tianjin 2 Jinan 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai8 Beijing7 Guangzhou5 Tianjin2 Jinan2
All 22 locations
Target enrolment
to

Triple-Negative Breast Cancer (TNBC) trials in China

24 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
NCT07752550Triple-Negative Breast Cancer (TNBC)
Harbin Medical University
Phase 2
120
Harbin
2026-07-30
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Recruiting
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
NCT07342283Triple Negative Breast Cancer (TNBC)
Affiliated Hospital of Nantong University
Phase 2
30
Nantong
2026-02-25
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
NCT07486089Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
NCT07208149Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
42
Beijing
2026-01-29
Recruiting
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06732323Triple-Negative Breast Cancer (TNBC)
Qilu Pharmaceutical Co., Ltd.
Phase 3
504
Beijing
2025-09-04
Not yet open
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT07153965Triple Negative Breast Cancer (TNBC), PD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital
Phase 2
47
Tianjin
2025-09-01
By invitation
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer๏ผˆUPGRADE-TNBC๏ผ‰
NCT06910072Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
32
Beijing
2025-07-21
Recruiting
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
NCT07394387Triple Negative Breast Cancer (TNBC)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
58
Nanjing
2025-01-01
Recruiting
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
NCT06735131Triple-Negative Breast Cancer (TNBC)
Sun Yat-sen University
Phase 2
60
Guangzhou
2024-12-20
Recruiting
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
NCT06793332Triple-Negative Breast Cancer (TNBC), Brain Metastases
Fudan University
Phase 2
39
Shanghai
2024-12-17
Active, closed
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
NCT07046195Hypofractionated Radiotherapy, Triple Negative Breast Cancer (TNBC), Immunotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
250
Guangzhou
2024-12-11
Not yet open
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
NCT06724263Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
DrugB1962
Tasly Biopharmaceuticals Co., Ltd.
Phase 2
120
Shanghai
2024-12
Not yet open
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
NCT06731153Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
Fudan University
Phase 2
40
Shanghai
2024-12
Recruiting
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer
Fudan University
Phase 2
160
Shanghai
2024-10-21
Active, closed
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621Triple Negative Breast Cancer(TNBC)
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Beijing, Changchun, Jinan
2022-12-20
Recruiting
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)
Fudan University
Phase 2
716
Shanghai
2022-11-01
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/triple-negative-breast-cancer-tnbc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies listing the condition Triple-Negative Breast Cancer (TNBC).

How many Triple-Negative Breast Cancer (TNBC) trials are recruiting in China?

13 of the 24 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Triple-Negative Breast Cancer (TNBC)), 24 studies
PhaseStudiesRecruitingShare
Phase 213854.2%
Phase 34216.7%
Phase 1/23312.5%
Phase 1208.3%
Observational104.2%
Phase 2/3104.2%

Most active sponsors

Lead sponsors with the most studies (Triple-Negative Breast Cancer (TNBC))
Lead sponsorStudiesRecruiting
Fudan University54
Sun Yat-sen University22
Tianjin Medical University Cancer Institute and Hospital20
AbbVie10
Adcentrx Therapeutics10
Affiliated Hospital of Nantong University11
Akeso11
Beijing Biotech11
Biotheus Inc.10
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.